[ad_1]
Article content material
The proxy voting deadline for XORTX shareholders to vote their proxies is 10:00 a.m. (Calgary time) on Monday, June 26, 2023.
- XORTX’s board of administrators recommends shareholders vote FOR the election of all director nominees, FOR the appointment of auditors of the following yr, and FOR the decision to approve the Firm’s inventory possibility plan.
- Shareholders who’ve questions or want help with voting their shares can contact Laurel Hill Advisory Group at 1-877-452-7184 or by e-mail at assistance@laurelhill.com.
Commercial 2
Article content material
Article content material
CALGARY, Alberta, June 23, 2023 (GLOBE NEWSWIRE) — XORTX Therapeutics Inc. (“XORTX” or the “Firm”) (NASDAQ: XRTX | TSXV: XRTX | Frankfurt: ANU), a late-stage medical pharmaceutical firm targeted on growing revolutionary therapies to deal with progressive kidney illness, want to remind shareholders that they’ve till 10:00 a.m. (Calgary time) on Monday, June 26, 2023 to vote their shares for the Firm’s upcoming annual and particular assembly of shareholders to be held on Wednesday, June 28, 2023 at 10:00 a.m. (Calgary time) (the “Assembly”).
Dr. Allen Davidoff, CEO of XORTX said, “XORTX has made substantial advances through the previous yr guided by our skilled and expert R&D group and our broadly skilled board of administrators. Because the Firm advances our late stage program in ADPKD towards the beginning of registration medical trial initiation, the Firm’s reliance upon our board of administrators particular person licensing, partnering and commercialization expertise will enhance considerably. Shareholders are inspired to vote and help the resolutions being voted at this yr’s Assembly to help a steady course of towards licensing deal and the purpose of constructing a excessive worth firm.”
Article content material
Commercial 3
Article content material
Shareholders are urged to fastidiously learn the knowledge round in reference to the Assembly. A replica of the knowledge round and all different assembly supplies is accessible on SEDAR at www.sedar.com and on XORTX’s web site at www.xortx.com. XORTX’s board of administrators recommends shareholders vote FOR all the proposed resolutions.
YOUR VOTE IS IMPORTANT REGARDLESS OF THE NUMBER OF SHARES YOU OWN.
PLEASE VOTE TODAY. THE PROXY CUT-OFF IS MONDAY, JUNE 26, 2023
AT 10 A.M. MOUNTAIN TIME.
Shareholder Help
Shareholders who’ve questions, or want help with voting their shares, ought to contact Laurel Hill Advisory Group, the proxy solicitation agent, by phone at +1 877-452-7184 (North America toll free) or + 1 416-304-0211 (outdoors North America), or by electronic mail at assistance@laurelhill.com.
Commercial 4
Article content material
About XORTX Therapeutics Inc.
XORTX is a pharmaceutical firm with two clinically superior merchandise in improvement: 1) our lead, XRx-008 program for ADPKD; and a couple of) our secondary program in XRx-101 for acute kidney and different acute organ harm related to Coronavirus / COVID-19 an infection. As well as, XRx-225 is a pre-clinical stage program for Sort 2 Diabetic Nephropathy. XORTX is working to advance its medical improvement stage merchandise that focus on aberrant purine metabolism and xanthine oxidase to lower or inhibit manufacturing of uric acid. At XORTX, we’re devoted to growing drugs to enhance the standard of life and future well being of sufferers. Extra info on XORTX is accessible at www.xortx.com.
Commercial 5
Article content material
For extra info, please contact:
Neither the TSX Enterprise Alternate nor Nasdaq has accredited or disapproved the contents of this information launch. No inventory change, securities fee or different regulatory authority has accredited or disapproved the knowledge contained herein.
Ahead Trying Statements
This press launch incorporates categorical or implied forward-looking statements pursuant to U.S. Federal securities legal guidelines. These forward-looking statements and their implications are primarily based on the present expectations of the administration of XORTX solely, and are topic to quite a lot of elements and uncertainties that might trigger precise outcomes to vary materially from these described within the forward-looking statements. Besides as in any other case required by legislation, XORTX undertakes no obligation to publicly launch any revisions to those forward-looking statements to replicate occasions or circumstances after the date hereof or to replicate the incidence of unanticipated occasions. Extra detailed details about the dangers and uncertainties affecting XORTX is contained beneath the heading “Danger Components” in XORTX’s Registration Assertion on Kind F-1 filed with the SEC, which is accessible on the SEC’s web site, www.sec.gov (together with any paperwork forming a component thereof or integrated by reference therein), in addition to in our studies, public disclosure paperwork and different filings with the securities commissions and different regulatory our bodies in Canada, which can be found on www.sedar.com.
Article content material
[ad_2]
Source link
Feedback
Postmedia is dedicated to sustaining a vigorous however civil discussion board for dialogue and encourage all readers to share their views on our articles. Feedback could take as much as an hour for moderation earlier than showing on the positioning. We ask you to maintain your feedback related and respectful. Now we have enabled electronic mail notifications—you’ll now obtain an electronic mail for those who obtain a reply to your remark, there may be an replace to a remark thread you observe or if a consumer you observe feedback. Go to our Community Guidelines for extra info and particulars on how one can regulate your email settings.
Be a part of the Dialog